Infection with influenza virus induces antibodies to the viral surface glycoproteins hemagglutinin and neuraminidase, and these responses can be broadly protective. To assess the breadth and magnitude of antibody responses, we sequentially infected mice, guinea pigs and ferrets with divergent H1N1 or H3N2 subtypes of influenza virus. We measured antibody responses by ELISA of an extensive panel of recombinant glycoproteins representing the viral diversity in nature. Guinea pigs developed high titers of broadly cross-reactive antibodies; mice and ferrets exhibited narrower humoral responses. Then, we compared antibody responses after infection of humans with influenza virus H1N1 or H3N2 and found markedly broad responses and cogent evidence for 'original antigenic sin'. This work will inform the design of universal vaccines against influenza virus and can guide pandemic-preparedness efforts directed against emerging influenza viruses.
r e s o u r c e Infections with seasonal influenza virus cause substantial morbidity and mortality every year on a global scale 1, 2 . In addition, influenza pandemics occur at irregular intervals and can claim millions of human lives 3 . The current vaccines against seasonal influenza virus are considered an efficacious countermeasure to prevent infection with this virus 2 . However, they usually induce strain-specific immune responses to the three to four strains included in the vaccine formulation. In contrast, infection with influenza virus can cause broader immune responses and longer lasting protection from re-infection by the same virus subtype [4] [5] [6] [7] .
Protective humoral immune responses to influenza virus are usually associated with antibodies to its surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). These proteins are readily accessible to antibodies on the virion itself or on infected cells, and antibodies that bind to them can often inhibit virus replication in vitro. The traditional correlate of protection provided by vaccines against seasonal influenza virus is based on antibodies that exhibit hemagglutination-inhibition (HI) activity. They block the interaction of the receptor-binding domain located on the HA head with its sialic-acid receptor 8 . Due to the high plasticity and ever-changing nature of the HA head domain, most antibodies that exhibit this function are relatively strain specific 9, 10 . Antibodies to NA can block its enzymatic function (NA inhibition), and NA-inhibition-active antibodies interfere with viral release and possibly also block the efficient migration of the virus through mucosal fluids and contribute to protection from disease 11, 12 . NA-reactive antibodies have been shown to be broadly reactive within a subtype but usually do not exhibit heterosubtypic activity 13, 14 . A third species of antibodies that exerts in vitro neutralizing activity is HA-stalk-reactive antibodies. Due to the conserved nature of the HA stalk, these antibodies are often cross-reactive within and across HA subtypes. Most stalk-reactive antibodies, with rare exceptions, are restricted in binding to group 1 HAs (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, HA-like H17 and HA-like H18) or group 2 HAs (H3, H4, H7, H10, H14 and H15) [15] [16] [17] [18] .
Notably, as a fourth antibody species, cross-reactive antibodies can also confer protection in vivo without showing neutralizing activity in vitro. Several mechanisms, including antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity, have been postulated to contribute to non-neutralizing cross-protection in vivo [19] [20] [21] [22] [23] . Antibody-dependent cell-mediated cytotoxicity has been shown to have a major role in the protective efficacy of HA-stalk-reactive antibodies as well 24 . These effector functions can be assessed through in vivo serum-transfer challenge experiments, for example, in the mouse model 25, 26 .
Cross-reactive antibodies are potentially important for protection from infection with 'drifted' (seasonal) and 'shifted' (pandemic) influenza viruses, but their prevalence and functionality is not well understood. Their presence might offer some protection, including lowering morbidity and mortality, during pandemics.
Better understanding of cross-reactive immunity in the human population is also important for the development of universal vaccine strategies against influenza virus that are designed to boost pre-existing antibodies to protective levels. Here we analyzed the titers and breadth of antibodies to the influenza virus surface glycoproteins HA and NA induced by infection in three animal models and in humans, as well as the prevalence of cross-reactive antibodies in the general human population. The resulting data sets represent the antibody crossreactome against the influenza virus surface glycoproteins.
RESULTS

Cross-reactive antibody profiles in animal models
To assess induction of cross-reactive antibodies, we sequentially infected mice, guinea pigs and ferrets with two divergent H1N1 or H3N2 strains of influenza virus (Supplementary Fig. 1) . The viral strains were chosen with the intention of reflecting a consecutive exposure history consistent with strains that circulated in humans and because these strains replicate well in mice, guinea pigs and ferrets ( Supplementary Fig. 2) . Furthermore, the animal species were chosen because they are the most relevant and most widely used animal models for influenza-virus research. For H1N1, the pre-pandemic, 1999 seasonal strain A/New Caledonia/20/99 (NC99) was chosen as the primary infection, followed by infection with the antigenically distinct 2009 pandemic H1N1 (pH1N1) isolate A/Netherlands/602/09 (NL09), an isolate antigenically identical to the prototype pandemic H1N1 strain A/California/04/09 (Cal09). Primary infection of mice led to the induction of antibodies that targeted mainly the HA of the homologous strain but also bound to heterologous H1 HAs and other related group 1 HAs (Fig. 1a) . Re-infection with the antigenically distinct NL09 H1N1 strain considerably boosted the broad antibody response to H1 and also increased reactivity to heterosubtypic group 1 HAs (Fig. 1b) . Notably, reactivity was highest to the H1 FM47 HA (phylogenetically situated between the HAs of the two infecting strains) ( Fig. 1b) . In general, reactivity to group 2 HAs (H3 HAs) was low or absent ( Fig. 1b) .
For the H3N2 arm of the experiment, animals were infected with the 1982 isolate A/Philippines/2/82 (Phil82), followed by infection with a more recent 2011 isolate A/Victoria/361/11 (Vic11); these are two strains separated by 29 years of antigenic drift ( Supplementary  Fig. 1 ). Primary infection of mice with Phil82 induced an immune response focused on the Phil82 H3 HA, with moderate cross-reactivity to other H3 HAs and low reactivity to heterosubtypic group 2 HAs (Fig. 1c) . Notably, we also detected low reactivity to several phylogenetically distant group 1 HAs, including H2 and H6 ( Fig. 1c) . Re-infection with the antigenically distinct Vic11 broadened the immune responses to heterologous H3 HAs and heterosubtypic group 2 HAs (Fig. 1d) . The reactivity to specific group 1 HAs was also boosted (Fig. 1d) . This cross-reactivity is noteworthy, since antibodies able to bind to the head domain of both H3 HAs and H2 HAs have previously been isolated from human donors 27 .
Reactivity to NA after single infection with NC99 H1N1 in the mouse model was focused on the N1 subtype ( Fig. 2a ). Reactivity to N1 was boosted, but no broadening of the response was detected after the second infection (with NL09 H1N1) ( Fig. 2b) . The NA response after infections with H3N2 was as narrow as the one detected after infections with H1N1 ( Fig. 2c,d) .
Next we compared the humoral cross-reactomes of mice, guinea pigs and ferrets ( Supplementary Figs. 3 and 4) . All three animal models are used for influenza-virus research, and intrinsic differences in each model's ability to induce cross-reactive antibodies might have important implications for the interpretation of pre-clinical data generated for candidate (universal) vaccines against influenza virus based on HA and NA. While heat-map-tree combinations are informative, they do not allow easy comparison of the cross-reactomes of different animal models. We thus plotted reactivity (presented as endpoint titers) against the percent difference in amino acids of the HAs compared with the sequence of the infection strain's HA. The resulting plots showed two-dimensional reactivity profiles that allowed visual comparison of the magnitude and breadth of responses in various animal models. While amino acid distances do not always correlate exactly with antigenic distances, we found it to be an adequate surrogate measure for the purposes of our data presentation ( Fig. 3 and Supplementary Fig. 5 ).
For sequential infection with H1N1, our analysis showed that mice mounted high titers of antibodies to the homologous and related HAs from the same subtype but had much lower titers of antibodies to distantly related HAs (Fig. 3a) . Guinea pigs exhibited a very broad plateau of cross-reactivity: titers of antibodies to the homologous H1 HA were as high as the titers of antibodies other distant group 1 HAs (Fig. 3b) . Finally, ferrets induced lower titers and narrow responses ( Fig. 3c) . Data obtained by sequential infection with H3N2 largely echoed these findings: narrower trends were observed for the response to NA, with low cross-group reactivity of guinea pigs after infection with H3N2 ( Fig. 2 and Supplementary Figs. 3 and 4) .
Our data suggested that guinea pigs had the intrinsic ability to mount broader antibody responses to influenza virus HAs than did mice or ferrets. Mice showed an intermediate response breadth, and ferrets, the 'gold standard' animal model for influenza virology, show low titers and little cross-reactivity ( Fig. 3 and Supplementary  Fig. 5 ). The number of N-linked-glycosylation sites on the HAs used as substrate, which could influence cross-reactivity, did not seem to correlate with antibody titers (Supplementary Fig. 6 ).
Cross-reactive antibody profiles in infected humans
After mapping the antibody cross-reactome directed against the influenza virus surface glycoproteins that was induced by infection in animal models, we measured the human response to infection. We tested serum from human patients who were admitted to the hospital and were diagnosed as being infected with pandemic H1N1 or seasonal H3N2. The cohort included 11 males and 8 females, with five subjects below 18 years of age, six subjects between 18 and 59 years of age, and eight subjects above 59 years of age ( Supplementary Table 1 ). Serum samples were obtained on the day of admission and 21 or 28 d after admission, and antibody induction was tested with a panel of recombinant HA and NA proteins. Notably, samples from patients infected with pandemic H1N1 induced a very broad response. The induction was greatest against group 1 HAs (ranging from tenfold to twentyfold), but the boost against group 2 HAs was almost as strong (ranging from sevenfold to ninefold) ( Fig. 4a-c and Supplementary  Figs. 7 and 8) . Antibodies to influenza B virus HA were not boosted ( Fig. 4a,b) , which indicated that the measured increase in reactivity was specific to influenza A virus antigen.
Samples from humans infected with H3N2 induced an antibody profile very different from that reported above. Reactivity to the homologous strain was induced (twentyfold), while induction to the next-closest H3 strain was significantly lower (eightfold) ( Fig. 4d,e ), which indicated that the infection induced mainly strain-specific antibodies. Induction was also observed against more distantly related group 2 HAs, while reactivity to group 1 HAs only increased marginally after infection with H3N2 ( Fig. 4d-f ). Again, antibodies to influenza virus B HA were not induced ( Fig. 4d,e ). When visualized as 'antigenic landscapes' , these differences become very clear ( Fig. 4c,f In summary, these data suggested that in humans, infection with pandemic H1N1 virus induced a broader antibody response than did infection with a seasonal H3N2 virus. The HA of pandemic H1N1 differs substantially from the HA of seasonal H1N1 strains to which humans have previously been exposed, while seasonal H3N2 has been circulating in humans for several decades 5, 28 . Our data therefore supported the hypothesis that secondary exposure to a highly divergent HA from the same HA group induced strong cross-reactive antibody responses. Notably, (homologous) responses to NA were stronger after infection with H3N2 than after infection with H1N1 ( Supplementary Fig. 9 ).
Evidence for 'original antigenic sin' in humans
Assessing the immediate immune response to acute infection with influenza virus is very important. However, measuring the cross-reactive antibody titers in the general human population in the absence of any immunological perturbation provides better understanding of potential protection in the context of pandemic preparedness. In addition, the baseline titers of cross-reactive antibodies might substantially affect the efficacy of (universal) vaccines against influenza viruses 29 . Here we analyzed serum samples from 90 subjects from a sex-balanced US cohort.
To gain more insight into the changes of antibody titers over time due to exposure to influenza virus, we stratified the subjects into In uenza A group 1
In uenza A group 2
In r e s o u r c e three age groups: 18-20 years of age ('young'), 33-44 years of age ('middle-aged'; born after the H2N2 subtype stopped circulating) and 49-64 years of age ('experienced'; potential prior exposure to the H2N2 subtype) ( Fig. 5a) . Subjects in the experienced age group were born when either a drifted version of the 1918 H1N1 virus or the H2N2 pandemic virus circulated. All subjects in this group should therefore have had prior exposure to H2N2 viruses. Subjects in the middle-aged group were born after H2N2 became extinct and was replaced by the group 2 H3N2 virus; therefore, this group had not been previously exposed to H2N2. The young cohort was used as a control group, with an exposure that was limited to recent group 1 and group 2 influenza A virus strains ( Fig. 5a) . Notably, the different exposure histories of the three age groups led to measurable differences in their cross-reactomes, including the breadth of the antibody response. The 'antigenic landscape' of the young group exhibited high titers of antibodies directed against recent H1 and H3, with low crossreactivity to moderately distant group 1 HAs (H5) and group 2 HAs (H4 and H14) ( Fig. 5b) . The middle-aged group had higher reactivity to H1 and H3 HAs (Fig. 5c) . Reactivity was particularly high to HAs that are similar to the H1 and H3 viruses that circulated during the childhood of these subjects and was lower to more recent H1 and H3 strains (Fig. 5c ). This group also had considerable cross-reactivity to H2 and H5 (group 1) and H4 and H14 (group 2) ( Fig. 5c) . The experienced group showed medium reactivity to both H1 and H3 but had unexpectedly high reactivity to H2 HA, which is the subtype to which this group might have been first exposed to during childhood ( Fig. 5d ). This group also exhibited high reactivity to H5 and H18 ( Fig. 5d) , which suggested that exposure to H2 followed by H1 boosted broadly cross-reactive antibodies 30 (endpoint titers, Supplementary  Fig. 10 ). Titers of antibodies to NA were in general low and were confined mostly to the N1 and N2 subtype (Supplementary Fig. 10 ).
An exception were the high titers of antibodies to N2 from the 1957 and 1968 pandemic viruses in the experienced group ( Supplementary  Fig. 10f) . These data provided evidence that childhood exposure to influenza virus induced long-lasting immune responses in adults that we were able to measure by ELISA, which would support the hypothesis of 'original antigenic sin' .
Functionality of human cross-reactive antibodies
Binding of antibodies to diverse HAs and NAs provides general information about the prevalence of cross-reactive antibodies in human serum. However, it is also important to study the biological activity of the antibody responses detected. Antibodies can protect via direct the inhibition or neutralization of virus and/or via effector functions mediated by the crystallizable fragment (Fc) of the antibody. Direct inhibition or neutralization can be assessed by micro-neutralization assays in vitro.
Here we used an assay setup that enhanced sensitivity by using multicycle viral growth in combination with purified immunoglobulin G (IgG) to minimize nonspecific inhibition. We investigated only r e s o u r c e HA-specific antibodies, which we achieved by using re-assortant viruses that express irrelevant NAs (Supplementary Fig. 10b,d,f) . We created six re-assortant viruses on the backbone of influenza virus strain A/PR/8/34 for this purpose: H1N8 (H1 from NC99), H5N8 (H5 from VN04), H9N4 (H9 from gfHoKo99), H3N8 (H3 from Phil82), H4N8 (H4 from duckCzech56) and H7N8 (H7 from Shanghai13). These viruses were selected to determine if the antibody titers measured by ELISA translated into a functional assay. IgG antibodies from the 90 subjects described above were purified, reconstituted to the original concentration in serum and tested against all six viruses.
Neutralizing activity directed against H1N8 was high for all age groups, as expected; the frequency of samples that reached a titer of at least 1:40 was as follows: 100% for the young cohort, 93.3% for the middle-aged cohort and 80% for the experienced cohort (Fig. 6a,b) . The neutralizing activity directed against H5N8 in samples from all cohorts was low, with only one subject in the middle-aged group reaching a titer of 1:40 (3.3%) (Fig. 6a,b) . However, greater neutralizing activity directed against H9N4 was detected, with 23.3% of the young and middle-aged subjects and 33.3% of the experienced subjects developing titers of at least 1:40 (Fig. 6a,b) . Similarly, neutralizing activity directed against H3N8 (group 2) was high, with 40% of the young subjects, 100% of the middle-aged subjects and 86.7% of the experienced subjects developing titers of 1:40 (Fig. 6c,d) . Neutralizing activity directed against H4N8 (0%, 16.7% and 3.3% for young middleaged and experienced subjects, respectively) and H7N8 (0%, 13.3% and 10% for young, middle-aged and experienced subjects, respectively) was considerably lower than that directed against H3N8 but was still detectable (Fig. 6c,d) .
Neutralization titers in general correlated with ELISA titers and pre-exposure history of the specific age groups (Figs. 5 and 6) . All subjects were probably exposed to the NC99 H1N1 strain, but titers inversely correlated with age: titers of antibodies directed against H1N8 were slightly higher in the young subjects and were lowest in the experienced subjects. The young subjects lacked a strong neutralizing response to H3N8, which expresses an HA (Phil82) to which they have not been previously exposed. Titers of antibodies directed against H3 were highest in the middle-aged subjects, who were probably exposed to a strain similar to Phil82 H3N2 early in life and were slightly lower in the experienced subjects, who were likely to have been first exposed to H1N1 and/or H2N2 viruses.
In vitro neutralization assays do not capture mechanisms of protection mediated by Fc and its receptor FcR, which might enhance the r e s o u r c e potency of antibodies in vivo 24, 26 . To explore the in vivo potency of serum from the three cohorts described above, we performed serumtransfer-challenge experiments in the mouse model ( Supplementary.  Fig. 11 ). Upon serum transfer, mice were challenged with the H3N8, H4N8 or H7N8 viruses used in the neutralization assay above. Lungs were harvested on day 3 and day 6 after infection, and viral titers in the lungs were assessed by plaque assay. For H3N8, only slightly lower viral titers were seen on day 3 after infection in mice passively immunized with serum relative to the viral titers in control mice that received serum depleted of immunoglobulins (Fig. 6e) . However, significantly lower viral titers were observed for all three groups on day 6 relative to the viral titers in the control mice, with the lowest viral titers in mice that received serum from the middle-aged cohort (Fig. 6f) . In this case, the reduction in viral titers in the lungs inversely correlated with the measured neutralization titers (Fig. 6c,f) . For H4N8, serum transfer reduced viral titers slightly but significantly on day 3 (Fig. 6f) . On day 6 after infection, the greatest effect on viral titers was seen for serum from the middle-aged cohort (Fig. 6e,f) . This reduction correlated with reactivity to H4 measured by ELISA but not with the findings of the neutralization assay ( Figs. 5 and 6) . This indicated that these antibodies measured by ELISA mediated their effects via FcR mechanisms. Serum transfer also had a slight effect on the replication of H7N8 both on day 3 and day 6 after infection, but the reduction in lung viral titers never reached significance (Fig. 6e,f) .
In summary, we demonstrated that cross-reactive antibodies in the general human population were functional both through direct neutralizing activity and through effector function.
DISCUSSION
It has been observed that infection of humans with influenza virus induces immune responses of greater quality, quantity and longevity than does vaccination against influenza virus 6, 7 . Cross-reactive and cross-protective antibodies have become the focus of influenzavirus research, since these antibodies can guide efforts to design broadly protective vaccines and therapeutics directed against influenza virus 31 . Here we used ELISAs to measure the antibody crossreactome directed against an extensive panel of influenza virus HAs and NAs (including all know subtypes) induced by infection in animal models and in humans. ELISAs are a very sensitive and useful tool with which to study antibody binding and cross-reactivity. r e s o u r c e However, they provide only limited insight into the biological activity of the measured responses. Using this technique, we found significant differences in both the breadth and the magnitude of the antibody response in models commonly employed for influenzavirus research. For all animal models, the immune response to HAs was focused mainly on either group 1 (after infection with H1N1) or group 2 (after infection with H3N2). Antibodies to NA were mostly subtype specific. Mice and guinea pigs induced high titers of antibody, while the responses measured for ferrets were lower. Guinea pigs exhibited an exceptionally broad response relative to that of the other animal models. Ferrets had a low and relatively narrow immune response when assessed by ELISA, even though they are capable of inducing high HI responses to homologous viruses. It has been noted that this HI response is usually focused on specific epitopes and is not reflective of the broad HI response of adult humans 32 . The extent of viral replication, which differs depending on viral strain and animal model, did not seem to be a major influence on the titers of crossreactive antibodies. The differences observed should be considered in choosing animal models for research on (universal) vaccines against influenza virus, since the model chosen might strongly influence the outcome of pre-clinical studies. Notably, none of these models accurately reflects the immune response in humans with pre-existing immunity and complicated histories of exposure to influenza virus. This highlights the need for human clinical trials for broadly protective and/or universal vaccines against influenza virus.
In the human population, infection with influenza virus induced substantial antibody cross-reactivity in terms of both magnitude and breadth. The reactivity was narrow after infection with H3N2 but was unexpectedly broad after infection with pandemic H1N1 virus. Also unexpectedly, the induction to group 2 HAs was almost as strong after infection with the pandemic H1N1 virus as after infection with H3N2 (with the exception of the matched H3 HA). This phenomenon might be explained by the greater phylogenetic and antigenic distance between the pandemic H1N1 strain and the pre-pandemic seasonal H1N1 strains (especially the variable head domain of the HAs) to which humans have pre-existing immunity 33 . It has been noted before that infection with and vaccination against the pandemic H1N1 virus induce antibodies directed against the stalk in humans because they present a novel head domain to the immune system, which then refocuses the antibody response toward the more conserved stalk domain to which memory exists 4, 5, 34 . However, the extent of this response has remained unknown so far. Also, an alternative hypothesis for this finding could be the small number of N-linked glycans on the HA of 2009 pandemic H1N1 viruses, in contrast to the large number of N-linked glycans on the HA of recent (e.g., Vic11) H3N2 viruses. While we cannot test this hypothesis in humans, we did not find any clear evidence of an influence of the number of putative N-linked glycosylation sites of the subtrate HAs on cross-reactivity. Only small amounts of serum were available from these infected subjects, which prevented our studying the functionality of these antibodies measured by ELISA. It is therefore not known whether the cross-group-reactive antibodies elicited by infection are also functional in vivo. Another limitation of our study is that the 'pre-infection' serum samples were obtained after the onset of symptoms. Therefore, the true pre-infection titers might be even lower and the antibody induction might be even higher than reported here.
While high titers of cross-reactive antibodies were detected in humans after natural infection, we wanted to further explore the breadth of the cross-reactome in the human population. This information is important, since high baseline reactivity to a specific subtype might amelio-rate disease and limit viral spread during a future pandemic with this subtype. We therefore studied the cross-reactome of the general human population by selecting 90 subjects that we grouped by three different age ranges (18) (19) (20) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) and 49-64 years of age) and based our analysis on their putative history of exposure to influenza virus.
We found that the cross-reactivity profiles depended on the preexposure history and were influenced by the viral strains first encountered during childhood. The young cohort, of subjects who grew up when H1N1 and H3N2 viruses circulated together, showed high reactivity to very recent isolates of these two subtypes, with limited cross-reactivity. The middle-aged cohort, of subjects who were first exposed to H3N2, had high titers of antibodies to H3 and other group 2 HAs but low titers of antibodies to H1 (which they encountered only later in life). Finally, the subjects in the experienced cohort were first exposed to H1N1 or H2N2 and exhibited very high titers of antibodies to H2, H1 and related subtypes such as H5. These findings provide evidence for the phenomenon in which the first HA subtype to which a person is exposed leaves an immunological imprint that will substantially affect the antibody cross-reactome that this person develops ('original antigenic sin'). The high titers of cross-reactive antibodies to group 1 HA in the experienced population might contribute to protection against new pandemic viruses that express group 1 HAs (such as H5, H6 or others). In general, we found that baseline titers of antibodies to H11, H12, H13 and others (group 1) and H7, H10 and H15 (group 2) were low. Of note, H7 influenza viruses 35 and, to some extent, also H10 influenza viruses 36 , have infected humans in Asia with a high case-fatality rate.
Notably, our findings also translated into in vitro and in vivo functional assays. In a virus-neutralization assay, we found that the group of middle-aged subjects with the highest titers of antibodies to H3 Phil82, as measured by ELISA, also most effectively neutralized an H3N8 virus based on this HA. Similarly, the group of young subjects had high titers of neutralizing antibodies to an H1N8 virus based on NC99, which is an HA from a strain that circulated during their childhood. Furthermore, these antibodies also conferred protection in an in vivo serum-transfer model.
In conclusion, we have created antigenic landscapes that describe the antibody cross-reactome directed against the glycoproteins of influenza virus in animal models and humans recently infected with influenza viruses. We found that the prevalence and breadth of the antibody cross-reactome of the general human population varied largely and depended on the individual history of exposure to influenza viruses. These data provide information for pandemic preparedness and the choice of animal models for the development of broadly protective vaccines against influenza virus. Finally, the wide prevalence of cross-reactive antibodies in humans would suggest that future strategies of universal vaccines that target the HA head, stalk or NA might be successful in boosting these antibody levels to protective titers.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. antibody titers of human serum samples against different HA subtypes, three-dimensional 'antibody landscapes' 43 were constructed. In these 'landscapes' , the distance between points in the horizontal plane (x-y coordinates) represents the amino-acid-sequence distance among strains, and the height (z coordinate) represents the titers of antibodies (geometric mean values) to corresponding strains on the horizontal plane. The horizontal plane was constructed by multi-dimensional scaling of the amino-acid-sequence distance 44, 45 . The sequence distances among strains were defined as the total number of amino acids that were different between corresponding HAs in the multiple sequence alignment of all the HAs used in this study. The sum of squared errors between the Euclidean distance in the two-dimensional plane and the HA sequence distance was minimized by the SMACOF algorithm 45 . The HA sequences were divided into two HA groups: one included H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and H18, and the other included H3, H4, H7, H10, H14 and H15. For each HA group, the surface of the 'antibody landscape' was approximated from antibody titers (geometric mean values) using multilevel B-splines. We used the mba.surf function implemented in the Multilevel B-spline Approximation package in R version 3.2.5.
Statistical analysis.
Statistical analysis was performed with GraphPad Prism 7. Microneutralization titers were compared by ordinary one-way ANOVAs followed by Tukey's multiple comparisons tests. The viral lung titers were compared by ordinary one-way ANOVAs followed by Dunnett's multiple comparison tests with the no-Ig group serving as the control group. The nonlinear regression function 'Plateau followed by one phase decay' was used to create nonlinear fit curves for the ELISA data.
Data availability. The data that support the findings of this study are available from the corresponding author upon request.
